<p>GH Research PLC（纳斯达克代码：GHRS - 获取免费报告）获得了覆盖该公司的十一家研究机构的平均推荐评级为 “适度买入”，Marketbeat Ratings 报告称。一位投资分析师给予该股票卖出评级，一位给予持有评级，九位给予该公司买入评级。在过去一年中，发布报告的分析师对该股票的平均 12 个月目标价为 40.1250 美元。</p>
<ul>
<li>3 只分析师认为价格将翻倍的快速增长股票</li>
</ul>
<p>几家研究机构对 GHRS 进行了评论。Needham &amp; Company LLC 将 GH Research 的目标价格从 31.00 美元上调至 32.00 美元，并在 3 月 6 日的研究报告中给予该股票 “买入” 评级。加拿大皇家银行将 GH Research 的目标价格从 33.00 美元上调至 40.00 美元，并在 1 月 23 日的报告中给予该股票 “跑赢大盘” 评级。Weiss Ratings 在 4 月 21 日的研究报告中重申了对 GH Research 的 “卖出（d-）” 评级。Guggenheim 在 3 月 10 日的研究报告中将 GH Research 的目标价格设定为 34.00 美元，并给予该公司 “买入” 评级。最后，Wolfe Research 在 1 月 6 日的研究报告中将 GH Research 的目标价格设定为 39.00 美元。</p>
<p><strong>阅读我们关于 GH Research 的最新研究报告</strong></p>
<h2>机构资金流入和流出</h2>
<p>大型投资者最近调整了对该股票的持有。Lynx1 Capital Management LP 在第三季度将其在 GH Research 的持仓增加了 27.5%。Lynx1 Capital Management LP 目前拥有 8,601,189 股该公司的股票，价值 122,997,000 美元，此前在上个季度增持了 1,854,238 股。RTW Investments LP 在第四季度将其在 GH Research 的持仓增加了 6.5%。RTW Investments LP 目前拥有 5,933,815 股该公司的股票，价值 75,359,000 美元，此前在上个季度增持了 364,251 股。Avoro Capital Advisors LLC 在第四季度购买了 GH Research 的新头寸，价值约 22,860,000 美元。Millennium Management LLC 在第三季度将其在 GH Research 的持仓增加了 324.1%。Millennium Management LLC 目前拥有 863,602 股该公司的股票，价值 12,350,000 美元，此前在此期间增持了 659,957 股。最后，Jefferies Financial Group Inc.在第四季度将其在 GH Research 的持仓增加了 0.4%。Jefferies Financial Group Inc.目前拥有 712,300 股该公司的股票，价值 9,046,000 美元，此前在上个季度增持了 2,988 股。56.90% 的股票目前由对冲基金和其他机构投资者持有。</p>
<h2>GH Research 下跌 1.9%</h2>
<p>纳斯达克：GHRS 周三开盘价为 21.28 美元。GH Research 的 12 个月低点为 9.46 美元，12 个月高点为 24.66 美元。该公司的市值为 13.2 亿美元，市盈率为-26.60，贝塔值为 1.27。该公司的 50 日移动平均线为 16.16 美元，200 日移动平均线为 15.08 美元。</p>
<p>GH Research（纳斯达克：GHRS - 获取免费报告）在 3 月 6 日最后发布了季度财报。该公司报告季度每股收益（EPS）为（0.23）美元，超出分析师共识预期的（0.29）美元 0.06 美元。平均而言，股票研究分析师预测 GH Research 在当前财年将发布-1.52 美元的每股收益。</p>
<h2>GH Research 公司简介</h2>
<p>（获取免费报告）</p>
<p>GH Research Holdings Inc 是一家临床阶段的生物技术公司，致力于通过应用灵感来自迷幻药的化合物开发新型神经精神疾病治疗方案。公司总部位于爱尔兰都柏林，专注于利用 5-美氧基-N-二甲基色胺（5-MeO-DMT）及相关分子的独特药理学，以满足心理健康领域的重大未满足医疗需求。</p>
<p>该公司的主导项目 GH001 是一种吸入式 5-MeO-DMT 制剂，已完成早期临床试验，评估其在难治性抑郁症中的安全性、耐受性和初步疗效。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 GH Research</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0hSUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0hSUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 GH Research 吗？</h2>
<p>在考虑 GH Research 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 GH Research 并不在名单上。</p>
<p>虽然 GH Research 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GHRS

基因改革 ETF - ARK

医疗业 ETF - Vanguard

<p>GH Research PLC（纳斯达克代码：GHRS）获得了来自十一家研究公司的 “适度买入” 平均评级。一位分析师将其评为卖出，一位评为持有，九位评为买入。12 个月的平均目标价为 40.13 美元。显著的目标价上调包括 Needham 将其上调至 32 美元，皇家银行将其上调至 40 美元。该股票目前交易价格为 21.28 美元，市值为 13.2 亿美元。GH Research 专注于开发用于治疗神经精神疾病的灵感来源于迷幻药的化合物</p>

<p>GH Research PLC (NASDAQ:GHRS - Get Free Report) has received an average recommendation of &#34;Moderate Buy&#34; from the eleven research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $40.1250.</p>
<div class="lb-trans"><p>GH Research PLC（纳斯达克代码：GHRS - 获取免费报告）获得了覆盖该公司的十一家研究机构的平均推荐评级为 “适度买入”，Marketbeat Ratings 报告称。一位投资分析师给予该股票卖出评级，一位给予持有评级，九位给予该公司买入评级。在过去一年中，发布报告的分析师对该股票的平均 12 个月目标价为 40.1250 美元。</p>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只分析师认为价格将翻倍的快速增长股票</li>
</ul>
</div><p>Several research firms have commented on GHRS. Needham &amp; Company LLC lifted their target price on shares of GH Research from $31.00 to $32.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, March 6th. Royal Bank Of Canada raised their price objective on GH Research from $33.00 to $40.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, January 23rd. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of GH Research in a research report on Tuesday, April 21st. Guggenheim set a $34.00 target price on GH Research and gave the company a &#34;buy&#34; rating in a research note on Tuesday, March 10th. Finally, Wolfe Research set a $39.00 target price on GH Research in a research report on Tuesday, January 6th.</p>
<div class="lb-trans"><p>几家研究机构对 GHRS 进行了评论。Needham &amp; Company LLC 将 GH Research 的目标价格从 31.00 美元上调至 32.00 美元，并在 3 月 6 日的研究报告中给予该股票 “买入” 评级。加拿大皇家银行将 GH Research 的目标价格从 33.00 美元上调至 40.00 美元，并在 1 月 23 日的报告中给予该股票 “跑赢大盘” 评级。Weiss Ratings 在 4 月 21 日的研究报告中重申了对 GH Research 的 “卖出（d-）” 评级。Guggenheim 在 3 月 10 日的研究报告中将 GH Research 的目标价格设定为 34.00 美元，并给予该公司 “买入” 评级。最后，Wolfe Research 在 1 月 6 日的研究报告中将 GH Research 的目标价格设定为 39.00 美元。</p>
</div><p><strong>Read Our Latest Research Report on GH Research</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 GH Research 的最新研究报告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Large investors have recently modified their holdings of the stock. Lynx1 Capital Management LP boosted its position in shares of GH Research by 27.5% in the third quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company's stock worth $122,997,000 after acquiring an additional 1,854,238 shares during the last quarter. RTW Investments LP increased its position in GH Research by 6.5% during the fourth quarter. RTW Investments LP now owns 5,933,815 shares of the company's stock worth $75,359,000 after purchasing an additional 364,251 shares during the last quarter. Avoro Capital Advisors LLC purchased a new position in GH Research during the fourth quarter worth approximately $22,860,000. Millennium Management LLC raised its stake in GH Research by 324.1% during the third quarter. Millennium Management LLC now owns 863,602 shares of the company's stock worth $12,350,000 after purchasing an additional 659,957 shares during the period. Finally, Jefferies Financial Group Inc. boosted its holdings in shares of GH Research by 0.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 712,300 shares of the company's stock valued at $9,046,000 after purchasing an additional 2,988 shares during the last quarter. 56.90% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近调整了对该股票的持有。Lynx1 Capital Management LP 在第三季度将其在 GH Research 的持仓增加了 27.5%。Lynx1 Capital Management LP 目前拥有 8,601,189 股该公司的股票，价值 122,997,000 美元，此前在上个季度增持了 1,854,238 股。RTW Investments LP 在第四季度将其在 GH Research 的持仓增加了 6.5%。RTW Investments LP 目前拥有 5,933,815 股该公司的股票，价值 75,359,000 美元，此前在上个季度增持了 364,251 股。Avoro Capital Advisors LLC 在第四季度购买了 GH Research 的新头寸，价值约 22,860,000 美元。Millennium Management LLC 在第三季度将其在 GH Research 的持仓增加了 324.1%。Millennium Management LLC 目前拥有 863,602 股该公司的股票，价值 12,350,000 美元，此前在此期间增持了 659,957 股。最后，Jefferies Financial Group Inc.在第四季度将其在 GH Research 的持仓增加了 0.4%。Jefferies Financial Group Inc.目前拥有 712,300 股该公司的股票，价值 9,046,000 美元，此前在上个季度增持了 2,988 股。56.90% 的股票目前由对冲基金和其他机构投资者持有。</p>
</div><h2>GH Research Trading Down 1.9%</h2>
<div class="lb-trans"><h2>GH Research 下跌 1.9%</h2>
</div><p>NASDAQ:GHRS opened at $21.28 on Wednesday. GH Research has a 12-month low of $9.46 and a 12-month high of $24.66. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of -26.60 and a beta of 1.27. The company's 50-day moving average is $16.16 and its two-hundred day moving average is $15.08.</p>
<div class="lb-trans"><p>纳斯达克：GHRS 周三开盘价为 21.28 美元。GH Research 的 12 个月低点为 9.46 美元，12 个月高点为 24.66 美元。该公司的市值为 13.2 亿美元，市盈率为-26.60，贝塔值为 1.27。该公司的 50 日移动平均线为 16.16 美元，200 日移动平均线为 15.08 美元。</p>
</div><p>GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings results on Friday, March 6th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.06. On average, equities research analysts forecast that GH Research will post -1.52 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>GH Research（纳斯达克：GHRS - 获取免费报告）在 3 月 6 日最后发布了季度财报。该公司报告季度每股收益（EPS）为（0.23）美元，超出分析师共识预期的（0.29）美元 0.06 美元。平均而言，股票研究分析师预测 GH Research 在当前财年将发布-1.52 美元的每股收益。</p>
</div><h2>GH Research Company Profile</h2>
<div class="lb-trans"><h2>GH Research 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.</p>
<div class="lb-trans"><p>GH Research Holdings Inc 是一家临床阶段的生物技术公司，致力于通过应用灵感来自迷幻药的化合物开发新型神经精神疾病治疗方案。公司总部位于爱尔兰都柏林，专注于利用 5-美氧基-N-二甲基色胺（5-MeO-DMT）及相关分子的独特药理学，以满足心理健康领域的重大未满足医疗需求。</p>
</div><p>The firm's lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.</p>
<div class="lb-trans"><p>该公司的主导项目 GH001 是一种吸入式 5-MeO-DMT 制剂，已完成早期临床试验，评估其在难治性抑郁症中的安全性、耐受性和初步疗效。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than GH Research</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 GH Research</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0hSUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=GHRS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in GH Research Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 GH Research 吗？</h2>
</div><p>Before you consider GH Research, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 GH Research 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 GH Research 并不在名单上。</p>
</div><p>While GH Research currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 GH Research 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

GH Research PLC (NASDAQ:GHRS) Given Average Recommendation of "Moderate Buy" by Brokerages

Market Beat

GH Research

标普生物技术 3 倍做多 - Direxion

标普全球医疗股指数 ETF - iShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

医疗业 ETF - SPDR

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

加拿大皇家银行

禧图集团

Jefferies Financial

GH Research PLC（NASDAQ:GHRS）被券商给予 “适度买入” 的平均评级